Literature DB >> 18637733

Induction of apoptosis in murine neuroblastoma by systemic delivery of transferrin-shielded siRNA polyplexes for downregulation of Ran.

Nicole Tietze1, Jaroslav Pelisek, Alexander Philipp, Wolfgang Roedl, Thomas Merdan, Peter Tarcha, Manfred Ogris, Ernst Wagner.   

Abstract

The polymer, OEI-HD, based on beta-propionamide-cross-linked oligoethylenimine and its chemical transferrin conjugate were evaluated for siRNA delivery into murine Neuro2A neuroblastoma cells in vitro and in vivo. An 80% silencing of luciferase expression in neuroblastoma cells, stably transfected with a luciferase gene, was obtained using standard OEI-HD polyplexes or transferrin-conjugated shielded OEI-HD polyplexes. The Ras-related nuclear protein Ran was selected as a therapeutically relevant target protein. Systemic delivery of transferrin-conjugated OEI-HD/RAN siRNA formulations (three intravenous applications at 3 days interval) resulted in >80% reduced Ran protein expression, apoptosis, and a reduced tumor growth in Neuro2A tumors of treated mice. The treatment was not associated with signs of acute toxicity or significant changes in weight, hematology parameters, or liver enzymes (AST, ALT, or AP) of mice. All our results demonstrate that OEI-HD/siRNA formulations can knockdown genes in tumor cells in vitro and in vivo in mice in the absence of unspecific toxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18637733     DOI: 10.1089/oli.2008.0112

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  14 in total

Review 1.  Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy.

Authors:  Yunching Chen; Leaf Huang
Journal:  Expert Opin Drug Deliv       Date:  2008-12       Impact factor: 6.648

2.  Ran out of the nucleus for apoptosis.

Authors:  Andrew Wilde; Yixian Zheng
Journal:  Nat Cell Biol       Date:  2009-01       Impact factor: 28.824

Review 3.  Alterations in the nucleocytoplasmic transport in apoptosis: Caspases lead the way.

Authors:  Gelina S Kopeina; Evgeniia A Prokhorova; Inna N Lavrik; Boris Zhivotovsky
Journal:  Cell Prolif       Date:  2018-06-26       Impact factor: 6.831

4.  Gene silencing and antitumoral effects of Eg5 or Ran siRNA oligoaminoamide polyplexes.

Authors:  Daniel Edinger; Raphaela Kläger; Christina Troiber; Christian Dohmen; Ernst Wagner
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

Review 5.  Gene therapy as a potential tool for treating neuroblastoma-a focused review.

Authors:  M D Kumar; A Dravid; A Kumar; D Sen
Journal:  Cancer Gene Ther       Date:  2016-04-15       Impact factor: 5.987

Review 6.  pH-Responsive nanoparticles for drug delivery.

Authors:  Weiwei Gao; Juliana M Chan; Omid C Farokhzad
Journal:  Mol Pharm       Date:  2010-10-27       Impact factor: 4.939

Review 7.  Targeted delivery systems for oligonucleotide therapeutics.

Authors:  Bo Yu; Xiaobin Zhao; L James Lee; Robert J Lee
Journal:  AAPS J       Date:  2009-03-19       Impact factor: 4.009

8.  An essential role for Ran GTPase in epithelial ovarian cancer cell survival.

Authors:  Véronique Barrès; Véronique Ouellet; Julie Lafontaine; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Mol Cancer       Date:  2010-10-13       Impact factor: 27.401

9.  Toward personalized cancer nanomedicine - past, present, and future.

Authors:  Alexander H Stegh
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

10.  Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA.

Authors:  Peter Järver; Thibault Coursindel; Samir El Andaloussi; Caroline Godfrey; Matthew Ja Wood; Michael J Gait
Journal:  Mol Ther Nucleic Acids       Date:  2012-06-12       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.